Apollo Therapeutics LLC, a group funded by three large pharma companies to invest in UK university research, has appointed Richard Butt as its chief executive. Dr Butt joins Apollo from Pfizer Inc where he spent 20 years in research and development. He has a particular interest in translational research, which he used at Pfizer to help bring about a series of clinical studies with external collaborators. Dr Butt has a PhD in biochemistry from University College London and a BSc in biochemistry from the University of York.
Apollo announced the appointment on 14 April 2016.
Copyright 2016 Evernow Publishing Ltd